Clinical Trial Update: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating REGN3500 alone and with dupilumab in adults with moderate-to-severe atopic dermatitis terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• REGN3500 (anti-IL-33 monoclonal antibody)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2021-11-01